Why it Matters
Concerns have grown over supply chain concentration and dependence on China for active pharmaceutical ingredients and other medical supplies. The East Asia and Pacific Subcommittee of the House Foreign Affairs Committee will discuss this issue at a hearing on Nov. 19 titled "The Hidden Chokepoint: China's Dominance in Pharmaceuticals."
Rep. Young Kim (R-CA) is chair and Rep. Ami Bera (D-CA) as ranking member. Three witnesses are listed: Ron Piervincenzi of U.S. Pharmacopeia, Andrew Rechenberg of the Coalition for a Prosperous America, and Thomas J. Bollyky of the Council on Foreign Relations.
Broader Context
On Oct. 16, China's Ministry of Commerce and Ministry of Science and Technology proposed export controls that include biopharmaceutical technologies and an interim registration requirement, with comments due Nov. 15, according to a Ropes & Gray analysis. That proposal concerns technology exports, not drug shipments.
The Bottom Line
The East Asia and Pacific Subcommittee will hear witnesses from a pharmacopeial standards body, a trade-focused coalition and a foreign policy think tank.
Access the Legis1 platform for comprehensive political news, data, and insights.
Spot something wrong? Report an issue with this article
